Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited has announced the issuance of 212,170 fully paid ordinary shares following the cashless exercise of 799,500 unlisted options. This move, which was made without disclosure under Part 6D.2 of the Corporations Act 2001, signifies the company’s adherence to regulatory compliance and may impact its market positioning by potentially increasing liquidity and shareholder value.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a company operating in the biotechnology sector, focusing on the development of innovative therapies for unmet medical needs.
Average Trading Volume: 1,497,148
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$309.1M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.